Global API Market Analysis
After witnessing a slump in demand and manufacturing index due to after-impact of economic recession, the global API market has been advancing at a significant growth rate in recent times. The market, which is likely to register a healthy CAGR of around 8% during 2012-2015, is supported by various key factors, such as emergence of India and China as prominent API manufacturing hub, patent expiration of blockbuster drugs and technological innovation to drive HPAPI segment. Further, impressive participation of private players is positively boosting the API production.
As per our report, “Global API Market Analysis”, the focus of global pharmaceutical and biotech industry participants is shifting towards cost-effective and quality-driven destinations, such as India and China. These countries provide cheap labor, high productivity, low-investment to set-up plant, good profit margins, among others. In addition, there is a set of supportive regulations that support the local manufacturing and at the same time encourage export between nations. With regards to liberal competitive scenario in India and China, the report has effectively provided a comparative analysis among countries with respect to key indicators, such as labor cost and productivity, price structure, and investment cost to set up plant.
It is worthy to mention here that the report takes into account those countries that are likely to provide profitable market opportunities for API market participants. In other words, the overall study analyzes the current and future outlook of API exporting nations, such as India, China and Italy. As our study shows that many countries in the world deal with API import or manufacture less number of APIs, we have not covered them.
Our study indicates that High Potency Active Pharmaceutical Ingredients (HPAPIs) is expected to play a major role in the future growth of global APIs market. With a worldwide value of US$ 9.2 Billion in 2011, the HPAPI market is growing at a CAGR of around 9% till 2015. Growth in the oncology therapeutics market will primarily drive the market. The report, in such a context, covers an in-depth study of global HPAPI market and bifurcate the segment by synthesis agent, branded and generics. In addition, it also elucidates the key developments with regards to HPAPIs in order to provide a comprehensive analysis.
The report provides an extensive research and prudent analysis on the worldwide API market and illustrates the industry segment into significant manner. Separate sections on therapeutic-wise analysis and emerging opportunities from High Potency APIs has also been covered separately in the report. Moreover, it provides an overview of the regulatory environment. The research contains exhaustive information on the market players, recent developments and geographical markets that will help clients in formulating market strategies and assess opportunity areas in the global APIs market.
As per our report, “Global API Market Analysis”, the focus of global pharmaceutical and biotech industry participants is shifting towards cost-effective and quality-driven destinations, such as India and China. These countries provide cheap labor, high productivity, low-investment to set-up plant, good profit margins, among others. In addition, there is a set of supportive regulations that support the local manufacturing and at the same time encourage export between nations. With regards to liberal competitive scenario in India and China, the report has effectively provided a comparative analysis among countries with respect to key indicators, such as labor cost and productivity, price structure, and investment cost to set up plant.
It is worthy to mention here that the report takes into account those countries that are likely to provide profitable market opportunities for API market participants. In other words, the overall study analyzes the current and future outlook of API exporting nations, such as India, China and Italy. As our study shows that many countries in the world deal with API import or manufacture less number of APIs, we have not covered them.
Our study indicates that High Potency Active Pharmaceutical Ingredients (HPAPIs) is expected to play a major role in the future growth of global APIs market. With a worldwide value of US$ 9.2 Billion in 2011, the HPAPI market is growing at a CAGR of around 9% till 2015. Growth in the oncology therapeutics market will primarily drive the market. The report, in such a context, covers an in-depth study of global HPAPI market and bifurcate the segment by synthesis agent, branded and generics. In addition, it also elucidates the key developments with regards to HPAPIs in order to provide a comprehensive analysis.
The report provides an extensive research and prudent analysis on the worldwide API market and illustrates the industry segment into significant manner. Separate sections on therapeutic-wise analysis and emerging opportunities from High Potency APIs has also been covered separately in the report. Moreover, it provides an overview of the regulatory environment. The research contains exhaustive information on the market players, recent developments and geographical markets that will help clients in formulating market strategies and assess opportunity areas in the global APIs market.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. APIS - AN INTRODUCTION
4. INDUSTRY PERFORMANCE
4.1 Current and Future Market Analysis to 2015
4.2 Market Segments
4.2.1 Branded and Generic APIs
4.2.2 Synthetic and Biotech APIs
4.3 Future Opportunity Assessment
5. COUNTRIES’ COMPARATIVE ANALYSIS: API MANUFACTURING
5.1 Labor Cost and Productivity
5.2 Price Structure
5.3 Investment Cost in Plant Set-up
6. ANALYSIS BY THERAPEUTIC SEGMENTS
6.1 Central Nervous System Disorders
6.2 Cardiovascular Diseases
6.3 Diabetes
6.4 Respiratory Disorders
6.5 Oncology
7. KEY GEOGRAPHICAL MARKETS
7.1 China
7.1.1 Current and Future Market Analysis to 2015
7.1.2 Regional Segmentation
7.1.3 Regulatory Environment
7.1.4 Future Opportunity Assessment
7.2 India
7.2.1 Current and Future Market Analysis to 2015
7.2.2 Regional Segmentation
7.2.3 Regulatory Environment
7.2.4 Future Opportunity Assessment
7.3 Italy
7.3.1 Current and Future Market Analysis to 2015
7.3.2 Regulatory Environment
7.3.3 Future Opportunity Assessment
7.4 Taiwan
8. HIGH-POTENCY APIS: AN EMERGING OPPORTUNITY
9. REGULATORY ENVIRONMENT
10. COMPETITIVE LANDSCAPE
10.1 Dr Reddy’s Laboratories
10.2 Cipla
10.3 Ranbaxy Laboratories
10.4 Zhejiang Hisun Pharmaceutical Co. Ltd.
10.5 Fabbrica Italiana Sintetici
10.6 Cambrex Corporation
10.7 Pfizer CentreSource
10.8 Teva Active Pharmaceutical Ingredients
10.9 Lonza
10.10 Daiichi Fine Chemicals
2. RESEARCH METHODOLOGY
3. APIS - AN INTRODUCTION
4. INDUSTRY PERFORMANCE
4.1 Current and Future Market Analysis to 2015
4.2 Market Segments
4.2.1 Branded and Generic APIs
4.2.2 Synthetic and Biotech APIs
4.3 Future Opportunity Assessment
5. COUNTRIES’ COMPARATIVE ANALYSIS: API MANUFACTURING
5.1 Labor Cost and Productivity
5.2 Price Structure
5.3 Investment Cost in Plant Set-up
6. ANALYSIS BY THERAPEUTIC SEGMENTS
6.1 Central Nervous System Disorders
6.2 Cardiovascular Diseases
6.3 Diabetes
6.4 Respiratory Disorders
6.5 Oncology
7. KEY GEOGRAPHICAL MARKETS
7.1 China
7.1.1 Current and Future Market Analysis to 2015
7.1.2 Regional Segmentation
7.1.3 Regulatory Environment
7.1.4 Future Opportunity Assessment
7.2 India
7.2.1 Current and Future Market Analysis to 2015
7.2.2 Regional Segmentation
7.2.3 Regulatory Environment
7.2.4 Future Opportunity Assessment
7.3 Italy
7.3.1 Current and Future Market Analysis to 2015
7.3.2 Regulatory Environment
7.3.3 Future Opportunity Assessment
7.4 Taiwan
8. HIGH-POTENCY APIS: AN EMERGING OPPORTUNITY
9. REGULATORY ENVIRONMENT
10. COMPETITIVE LANDSCAPE
10.1 Dr Reddy’s Laboratories
10.2 Cipla
10.3 Ranbaxy Laboratories
10.4 Zhejiang Hisun Pharmaceutical Co. Ltd.
10.5 Fabbrica Italiana Sintetici
10.6 Cambrex Corporation
10.7 Pfizer CentreSource
10.8 Teva Active Pharmaceutical Ingredients
10.9 Lonza
10.10 Daiichi Fine Chemicals
LIST OF FIGURES
Figure 4-1: Global - API Market (Billion US$), 2011-2015
Figure 4-2: Global - Share of Captive and Merchant Market in API Market (2011)
Figure 4-3: Global - API Captive Market (Billion US$), 2011-2015
Figure 4-4: Global - API Merchant Market (Billion US$), 2011-2015
Figure 4-5: Global - Share of Branded and Generic APIs in API Merchant Market (2011)
Figure 4-6: Global - Generic API Merchant Market (Billion US$), 2011-2015
Figure 4-7: Global - Branded API Merchant Market (Billion US$), 2011-2015
Figure 4-8: Global - Share of Synthetic and Biotech APIs in API Market (2011)
Figure 5-1: Global - Price Structure for Pharmaceutical Fine Chemicals in US, India and China (%)
Figure 7-1: China - Pharmaceutical Industry by Segment (2010)
Figure 7-2: China - API Merchant Market (Billion US$), 2011-2015
Figure 7-3: China - Share in Global API Merchant Market (2011)
Figure 7-4: China - Generic API Merchant Market (Billion US$), 2011-2015
Figure 7-5: China - Share in Global Generic API Merchant Market (2011)
Figure 7-6: India - API Merchant Market (Billion US$), 2011-2015
Figure 7-7: India - Share in Global API Merchant Market (2011)
Figure 7-8: India - Generic API Merchant Market (Billion US$), 2011-2015
Figure 7-9: India - Share in Global Generic API Merchant Market (2011)
Figure 7-10: Italy - API Merchant Market (Billion US$), 2011-2015
Figure 7-11: Italy - Share in Global API Merchant Market (2011)
Figure 7-12: Italy - Number of API Producers and Manufacturing Plants (1991, 2000 & 2009)
Figure 7-13: Italy - Generic API Merchant Market (Billion US$), 2011-2015
Figure 7-14: Italy - Share in Global Generic API Merchant Market (2011)
Figure 7-15: Taiwan - API Market (Billion NT$), 2010 & 2011
Figure 8-1: Global - HPAPI Market (Billion US$), 2011-2015
Figure 8-2: Global - Share of Synthetic and Biotech HPAPIs in HPAPI Market (2011)
Figure 8-3: Global - Share of Generics and Branded in HPAPI Market (2011)
Figure 4-1: Global - API Market (Billion US$), 2011-2015
Figure 4-2: Global - Share of Captive and Merchant Market in API Market (2011)
Figure 4-3: Global - API Captive Market (Billion US$), 2011-2015
Figure 4-4: Global - API Merchant Market (Billion US$), 2011-2015
Figure 4-5: Global - Share of Branded and Generic APIs in API Merchant Market (2011)
Figure 4-6: Global - Generic API Merchant Market (Billion US$), 2011-2015
Figure 4-7: Global - Branded API Merchant Market (Billion US$), 2011-2015
Figure 4-8: Global - Share of Synthetic and Biotech APIs in API Market (2011)
Figure 5-1: Global - Price Structure for Pharmaceutical Fine Chemicals in US, India and China (%)
Figure 7-1: China - Pharmaceutical Industry by Segment (2010)
Figure 7-2: China - API Merchant Market (Billion US$), 2011-2015
Figure 7-3: China - Share in Global API Merchant Market (2011)
Figure 7-4: China - Generic API Merchant Market (Billion US$), 2011-2015
Figure 7-5: China - Share in Global Generic API Merchant Market (2011)
Figure 7-6: India - API Merchant Market (Billion US$), 2011-2015
Figure 7-7: India - Share in Global API Merchant Market (2011)
Figure 7-8: India - Generic API Merchant Market (Billion US$), 2011-2015
Figure 7-9: India - Share in Global Generic API Merchant Market (2011)
Figure 7-10: Italy - API Merchant Market (Billion US$), 2011-2015
Figure 7-11: Italy - Share in Global API Merchant Market (2011)
Figure 7-12: Italy - Number of API Producers and Manufacturing Plants (1991, 2000 & 2009)
Figure 7-13: Italy - Generic API Merchant Market (Billion US$), 2011-2015
Figure 7-14: Italy - Share in Global Generic API Merchant Market (2011)
Figure 7-15: Taiwan - API Market (Billion NT$), 2010 & 2011
Figure 8-1: Global - HPAPI Market (Billion US$), 2011-2015
Figure 8-2: Global - Share of Synthetic and Biotech HPAPIs in HPAPI Market (2011)
Figure 8-3: Global - Share of Generics and Branded in HPAPI Market (2011)
LIST OF TABLES
Table 3-1: Classification of Bulk Drugs
Table 5-1: Global - Fine Chemical Industry Labor Cost and Productivity in Key Regions (2010)
Table 5-2: Global - Investment Cost Comparison for Multi-Purpose Pharmaceutical Fine Chemical Plants in Key Countries
Table 7-1: China - Number of API Companies by Province
Table 7-2: India - Number of Bulk Drugs Manufacturing Units
Table 7-3: Taiwan - Number of Pharmaceutical Licenses by Type (2010)
Table 9-1: Scope of Authority for Regulatory Agencies
Table 3-1: Classification of Bulk Drugs
Table 5-1: Global - Fine Chemical Industry Labor Cost and Productivity in Key Regions (2010)
Table 5-2: Global - Investment Cost Comparison for Multi-Purpose Pharmaceutical Fine Chemical Plants in Key Countries
Table 7-1: China - Number of API Companies by Province
Table 7-2: India - Number of Bulk Drugs Manufacturing Units
Table 7-3: Taiwan - Number of Pharmaceutical Licenses by Type (2010)
Table 9-1: Scope of Authority for Regulatory Agencies
